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Dr Joseph Ricotta (Atlanta, Ga). How long were these
patients anticoagulated for? Was there variability between the
studies in terms of the duration of anticoagulation therapy?
Dr Randall R. De Martino. There was some variation. We
required a minimum of 30 days because most of these were
postoperative patients and that is what reporting goes to, although
I think treatment should last for at least 6 weeks. We did a
sensitivity analysis of outcomes by studies reporting 6 weeks of
anticoagulation treatment or less. There was no change in the
effect on clot propagation or PE.
Dr Ricotta. The longer the duration?
Dr De Martino. Correct.oleus plexus clots in the absence of the named tibial vessel
lots?
DrDeMartino.We did not look specifically at gastrocnemius
r soleal clots in this study. We were focused on tibial and peroneal
hrombi. I think that they may follow a similar pattern, although
e can’t make any conclusions based on this study. Other studies
hat have addressed that question and maybe a compilation of
hose studies can help identify if they are similar in characteristics.
ut I don’t know that the clinical history of them is as well defined
s is tibial and peroneal.
Dr Firas Mussa (New York, NY). Your last bullet suggests
uture studies. Can you elaborate on design of those studies?Dr De Martino. I think there is still clinical equipoise as to
hether or not we can treat or not treat these patients. Based on
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Volume 56, Number 1 De Martino et al 237the data and the studies that are available, I think that there is still
a debate about this. I think clinical randomized trials will need to
assess the benefits and the harms of treatment, including bleeding,
mortality rates, and post-thrombotic syndrome. I am aware of one
ongoing clinical study in Europe, but I am unaware of the current
enrollment status. I was told yesterday in discussion, the University
of Washington has applied for a grant to perform a randomized
trial for this, and we hope that that will be funded and shed light on
this topic.
Dr Cynthia Shortell (Durham, NC). It is no surprise that
anticoagulation prevents thrombotic complications of calf vein
clot. The question has always been, when is the risk of anticoagu-
lation worth the benefit? And in calf vein thrombosis, that issue
gets down to what the risks of those patients are. One would intuit
that high-risk patients with calf clots, such as neurosurgical patients
or immobile patients, would be at higher risk, but that’s unknown
at this point. Did any of the studies that you included contain that
information? And if so, do you think you could use it to help us
identify those patients with calf clot that would really benefit from
anticoagulation?
Dr De Martino. I think we agree that there are patients who
are at higher risk. Several of these studies did try to identify specific
risk factors that would identify those patients with thrombi that are
going to propagate or cause PE. The most consistent risk factor
identified was inpatient status. Many other patient-level variables
that they were able to analyze were not predictive in their analyses.
We didn’t include that type of review in the present study, but that
is what I have been able to extract from the data that is available to
date.
DrMarkMeissner (Seattle, Wash). I was somewhat surprised
that although bleeding was heterogeneous, pulmonary embolism
and thrombus propagation was remarkably homogeneous. I think
this is surprising, because perhaps even more so than with proximal
vein thrombosis, calf vein thrombosis is often perceived to be a
heterogeneous disease with the risk of complications based on the
underlying risk factors for thrombosis. Your analysis seems to imply
that all calf vein thrombi should be treated as equal, which may not
be correct. Can you explain the homogeneity of your findings?
Dr De Martino: In regards to PE and clot propagation, I
think our pooled summary was homogeneous because of our strict
entry criteria. There are other studies reported on calf DVT that
were excluded because they didn’t meet this criteria. I think that
helped in creating a homogeneous estimate.
i
oThemajority of studies did report on PE and clot propagation.
ery few studies reported bleeding andmortality complications, so
he data that we were able to extract were sparse and spread across
ight studies, where only two to three may have contributed to the
ata, and I think that that affected our ability to make a homoge-
eous summary effect.
I think that while we were able to make a homogeneous study
ffect, we acknowledge that the strength of our findings comes
rom the quality of the studies that they were derived from. And so
robust clinical trial will really answer this question in the best light
ossible.
Dr Peter Gloviczki (Rochester, Minn). Did you notice a
ifference in symptomatic and asymptomatic calf vein thrombosis,
r were all these patients symptomatic?
Dr De Martino. We didn’t perform a formal subgroup anal-
sis of studies that were symptomatic or asymptomatic. Approxi-
ately half of the studies identified their patients as symptomatic,
wo of those four being the randomized controlled trials. But we
re unable to make a comment about whether the symptomatic
tatus does make a difference.
DrGloviczki.Andwas the diagnosis of PEmade using similar
echniques in these studies?
DrDeMartino.The diagnosis of PE was similar in all but one
tudy, which used a combination of V/Q scan and clinical diagno-
is based on patients with a sudden death that was preceded by
apid leg swelling. And so it was felt that that was a clinical
iagnosis of PE and we did include that.
Dr Roger Shinnerl (Evansville, Ind). I was wondering if you
ould please tell me if I am wrong, but I was left with the distinct
mpression, after looking at your data briefly, that all of the positive
esults were out of one study, the Pellegrini study. And that
isturbs me. Does that not make that study an outlier? And even if
ot, should we really be endorsing that finding with the results of
pooled analysis?
Dr De Martino. That one study was a nested case-control
tudy within a randomized trial. While they did identify a lot of
utcomes, I do not think that their methods were any different
han the other randomized trial that would make me think that
hey should be excluded or be an outlier. I think the fact that
ur summary of facts remained homogeneous despite their
nclusion attests that it was appropriate to include them within
ur analysis.
